Evidence map›Paper›PMID 34791556›Full record

ArticleBulletin of experimental biology and medicine2021

Evaluation of the Anti-Viral Activity of Human Recombinant Interferon Lambda-1 against SARS-CoV-2.

P G Madonov, V A Svyatchenko, S S Legostaev, N A Kikhtenko, A A Kotlyarova, L A Oleinik, G I Baikalov

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Pharmacokinetic Parameters of Oral Pegylated IFN-λ1.Bulletin of experimental biology and medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

P G MadonovResearch Institute of Clinical and Experimental Lymphology - an Affiliated Branch of the Federal Research Centre Institute of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.
V A SvyatchenkoState Research Center of Virology and Biotechnology Vector, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
S S LegostaevState Research Center of Virology and Biotechnology Vector, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
N A KikhtenkoResearch Institute of Clinical and Experimental Lymphology - an Affiliated Branch of the Federal Research Centre Institute of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.
A A KotlyarovaResearch Institute of Clinical and Experimental Lymphology - an Affiliated Branch of the Federal Research Centre Institute of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.
L A OleinikResearch Institute of Clinical and Experimental Lymphology - an Affiliated Branch of the Federal Research Centre Institute of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia. larisaoleynik81@gmail.com.
G I BaikalovResearch Institute of Clinical and Experimental Lymphology - an Affiliated Branch of the Federal Research Centre Institute of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.
Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing · RUInstitute of Cytology and Genetics · RURussian Academy of Sciences · RUInstitute of Clinical and Experimental Lymphology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The antiviral activity of recombinant human IFN-lambda type 1 (IFNλ-1) against culture strain of SARS-CoV-2 virus was determined by infecting a highly sensitive VeroE6 coronavirus cell culture after preincubation test (the cell monolayer was incubated with 4-fold dilutions of IFNλ-1 in a concentration range of 0.16-42,500 ng/ml in a culture medium for 12 h at 37°C) and without preincubation (simultaneous addition of different concentrations of IFNλ-1 and SARS-CoV-2 infection in a dose of 102 TCID50). The created recombinant human IFNλ-1 demonstrated obvious antiviral activity against SARS-CoV-2 virus in vitro. In the tests with and without preincubation, IFNλ-1 exhibited significant activity, although somewhat lower in variant with simultaneous addition of IFNλ-1 and virus to the cell culture. It should be noted that the antiviral effect of IFNλ-1 was observed in a wide range of concentrations.

Indexed as

AnimalsAntiviral AgentsChlorocebus aethiopsCloning, MolecularCOVID-19COVID-19 Drug TreatmentEscherichia coliGene ExpressionHumansInterferon LambdaInterferonsInterleukinsRecombinant ProteinsSARS-CoV-2Vero CellsViral LoadAntiviral AgentsInterferon Lambdainterferon-lambda, humanInterferonsInterleukinsRecombinant Proteinsrecombinant human interferon λ-1SARS-CoV-2specific antiviral activity

Identifiers

PMID34791556
PMCPMC8598276
OpenAlexW3188137703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.